Loading…
← CockpitCompetitor Analysis › ASKER.ST Asker Healthcare Group ABOpen in the cockpit ↗

Asker Healthcare Group ABASKER.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Distributors

Nordic distributor of medical devices and equipment, supplying hospitals and clinics across Scandinavia.

≈ A Nordic medical-supply distributor like a smaller Owens & MinorMomentum weak 25
Mkt cap
$2.69B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$3.26M
20-day average traded
Fwd P/E
24.8×
forward earnings
ROIC−WACC
+2.8 pp
WACC 5.0%
Hurdle
-8 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · SEKSEK 71.40
1D-0.4%
1W-4.0%
1M+2.1%
3M-7.0%
6M-14.5%
YTD-15.4%
1Y-24.4%
ATR %3.6%
52w lowhigh25.3% off high

What Asker Healthcare does

Nordic distributor of medical devices and equipment, supplying hospitals and clinics across Scandinavia.

In one line: A Nordic medical-supply distributor like a smaller Owens & Minor.

Products and services

  • Medical device distribution
  • Hospital/clinic equipment supply
  • Specialty medical consumables

Customers

  • Hospitals
  • Clinics
  • Healthcare providers

Where it sits in the supply chain

  • Health Care
  • Medical distribution
  • Medical device/equipment wholesale…

What could go right

  • Nordic healthcare spending growth
  • Bolt-on distribution acquisitions

What could go wrong

  • Thin distribution margins
  • Hospital procurement/tender pricing pressure

Moat: none (scale, distribution). Distribution scale across the Nordics helps logistics efficiency, but medical distribution margins are thin and competitive.

Headquarters: Stockholm, Sweden · Founded: 2016 · Employees: 4,580

Named competitors

Asker Healthcare at a glance

Size Asker Healthcare (ASKER.ST) is a Sweden Health Care company (Medical Distributors) with a market value of $2.69B, the 62nd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 71.40 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against +7.9% for the median peer and +2.8% for the Sweden market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 11.7% over the last twelve months (peer median +5.5%); the operating margin is 7.1% (peer median 3.0%).

Valuation It trades at 24.8× forward earnings against a peer median of 15.9× (most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 109ASKER.ST 85
Six months, rebased to 100: Asker Healthcare against the median of its 20 peers (local-currency closes).

Asker Healthcare financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 18.6BSEK 16.8BSEK 15.0BSEK 13.5BSEK 11.7B
Revenue growth—+12%+12%+15%—
Gross profitSEK 6.74BSEK 6.05BSEK 5.33BSEK 4.02BSEK 3.44B
EBITDASEK 2.35BSEK 2.09BSEK 1.61BSEK 1.16BSEK 1.08B
Net incomeSEK 756MSEK 492MSEK 360MSEK 203MSEK 430M
Free cash flowSEK 994MSEK 738MSEK 1.07BSEK 968MSEK 914M
Capital expenditureSEK 445MSEK 590MSEK 348MSEK 151MSEK 123M
Total debtSEK 6.97BSEK 5.81BSEK 5.96BSEK 4.97BSEK 4.74B

Quarterly statements and history in the cockpit →

Asker Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%+20%278400893099873349AMP7459600998RDC3360GALEDKSH6005877476DOCM1099301584600713603368ARJO-BASKER.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Asker Healthcare is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%10×20×278499873349AMP745960099881293360GALEDKSH60058774761099603368ARJO-BASKER.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Asker Healthcare is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%27840089309987AMP60099881293360GALEDKSH301584ASKER.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Asker Healthcare is the large dot.

Asker Healthcare competitors and peer comparison

Head to head with its named competitors (ASKER.ST vs HSIC vs ALIF-B.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Asker Healthcare ASKER.ST$2.69B-14%+12%7%24.8×4.7%
Henry Schein HSIC$9.47B+17%+6%6%14.7×10.2%
AddLife ALIF-B.ST$2.13B+15%+2%8%39.0×21.1%

How Asker Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Asker Healthcare against its 20 peers (data as of 18 Nov 2026)
MeasureASKER.STPeer medianRank in peer set
1-month return+2.1%+1.9%11th highest of 21
6-month return-14.5%+7.9%2nd lowest of 21
Distance from 52-week high-25.3%-14.3%3rd lowest of 21
Revenue growth (TTM)+11.7%+5.5%2nd highest of 21
Operating margin7.1%3.0%4th highest of 21
Forward P/E24.8×15.9×most expensive of 16
Growth the price implies (Req g, 7 yrs)4.7%-3.7%4th most demanding of 17
Growth delivered (Del g)+12.7%+4.6%2nd highest of 17
Hurdle (Req g minus delivered)-8.0 pp-8.9 pp8th most demanding of 17
ROIC minus cost of capital+2.8 pp+1.6 pp7th highest of 21
EV / EBITDA14.3×8.0×2nd most expensive of 6
Net debt / EBITDA2.6×0.5×4th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%

Questions

Who are Asker Healthcare's main competitors?
Named competitors: Owens & Minor (private or unlisted), Henry Schein (HSIC), AddLife (ALIF-B.ST). The cockpit's measured peer set (industry) also includes Alfresa (2784.T), Hanmi Science (008930.KS), Suzuken (9987.T), COSMOS Pharmaceutical (3349.T), Amplifon (AMP.MI), MEDIPAL (7459.T).
Is Asker Healthcare expensive compared with its peers?
On forward p/e it trades at 24.8× against a peer median of 15.9×, most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Asker Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against +7.9% for the median peer; over one year -24.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.